Nature Reviews Clinical Oncology

Article	Citations
Tasadenoturev active in DIPG	1296
A new standard of care for advanced-stage urothelial carcinoma	957
From little subclones grow mighty oaks	917
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	894
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	871
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	743
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	730
Novel ICI–TKI combination improves HCC outcomes	668
Ecological management of the microbiota in patients with cancer	668
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	647
Hodgkin lymphoma: great progress with room for improvement	572
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines	544
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	536
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	507
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	476
The emerging roles of circRNAs in cancer and oncology	452
Current understanding and management of CAR T cell-associated toxicities	417
Gut microbiota in colorectal cancer development and therapy	401
Contrasting results with second-line CAR T cells in large B cell lymphoma	395
Sacituzumab tirumotecan improves OS in mTNBC	386
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	365
Ponatinib superior to imatinib in Ph+ ALL	355
Mortality is similar with active monitoring	354
From ESMO 2022	353
Understanding and overcoming multidrug resistance in cancer	330

Minimal residual disease as a target for liquid biopsy in patients with solid tumours	319
Belzutifan as a new option in pheochromocytomas and paragangliomas	268
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	267
Humanized mouse models for immuno-oncology research	266
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	262
Harnessing cytokines and chemokines for cancer therapy	261
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	259
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	252
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	252
Survival benefit with second-line combination in endometrial cancer	250
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	249
Unresectable stage III non-small-cell lung cancer: state of the art and challenges	246
Harnessing big data to characterize immune-related adverse events	242
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	240
Craniospinal irradiation improves leptomeningeal metastasis control	237
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	232
Spatial landscapes of cancers: insights and opportunities	227
Improving outcomes in patients with oesophageal cancer	215
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	210
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	203
Biomarkers for immunotherapy of hepatocellular carcinoma	183
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	178
New CAPSTONE of SCLC therapy?	177
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	177
SHINE a light: frontline ibrutinib for MCL	173
Women with clinically node negative breast cancer can safely avoid axillary surgery	165
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	165
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	164
From ESMO 2023: advances in lung cancer	164
DREAMseq of therapy for BRAF-mutant melanoma	157
Prospective comparisons support the use of navigational bronchoscopy	148
Aumolertinib is effective in NSCLC	145
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma	138
Targeting chromosomal instability in patients with cancer	130
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond	127
Circulating tumour DNA — looking beyond the blood	123
Domvanalimab plus zimberelimab shows promise in upper-tract cancers	121
Long-term outcomes following CAR T cell therapy: what we know so far	116
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	116
Mitigating acute chemotherapy-associated adverse events in patients with cancer	114
Response to neoadjuvant endocrine therapy complements recurrence score	112
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	110
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	106
From the ESMO Congress 2023	105
Multiomics STEP up in correlative analysis of response to CAR T cells	105
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	104
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	103
Newly approved cancer drugs in China — innovation and clinical benefit	102
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	99
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	97

HAIC-FO improves outcomes in HCC	95
Lung cancer in patients who have never smoked — an emerging disease	94
Claudin 18.2 as a novel therapeutic target	92
Clinical implications of T cell exhaustion for cancer immunotherapy	86
Enhancing immunotherapy with tumour-responsive nanomaterials	86
Targeted biopsy reduces detection of clinically insignificant cancer	85
Combining CAR T cells effective in RRMM	85
T-DXd effective as second-line therapy in G/GEJ cancers	85
Second-line tarlatamab improves OS in SCLC	83
Less-frequent surveillance is noninferior to annual mammography	80
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	78
Two decades of advances in clinical oncology — lessons learned and future directions	74
Translating biological insights into improved management of endometrial cancer	71
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	70
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	68
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	67
Barriers in access to oncology drugs — a global crisis	67
BrECADD raises the bar in classical Hodgkin lymphoma	66
HSCT prolongs remission of high-risk CTCLs	65
Nirogacestat effective in desmoid tumours	64
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	63
Promise with co-administration of CAR T cells	63
Efficacy of TILs confirmed	63
Thermal ablation is safer than resection of colorectal liver lesions	62
Cured but breathless: the growing burden of DIILD in cancer survivors	61
Promising OS with oncolytic virotherapy	60
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	57
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	55
Non-financial conflicts of interest	55
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	53
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	48
Exploiting bacteria for cancer immunotherapy	47
The current state of the art and future trends in RAS-targeted cancer therapies	47
GPRC5D-CAR T cells active in MM	45
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	44
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	43
Repotrectinib effective in ROS1-fusion-positive NSCLC	40
Neoadjuvant pembrolizumab improves outcomes	40
LAG3 inhibition improves outcomes	39
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	38
KN046 shows tolerability and activity in TNBC	37
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	36
Belzutifan is active in VHL-related cancers	35
Problematic crossovers in cancer drug trials	34
Integrated MRI-guided radiotherapy — opportunities and challenges	33
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	32
The emerging roles of γδ T cells in cancer immunotherapy	32
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	31
CAR T cells induce durable remission of neuroblastoma	31
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	29
Axicabtagene effective in indolent NHL	27
National value-based pricing negotiation for oncology drugs — lessons from China	26
Personalizing adjuvant therapy for patients with colorectal cancer	25
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	24
GPRC5D as a novel immunotherapeutic target in multiple myeloma	23
Treatment of NSCLC after chemoimmunotherapy — are we making headway?	21
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib	21
Laparoscopic TME is non-inferior	20
PERSEUS triumphs — efficacy of daratumumab confirmed in transplant-eligible NDMM	19
Epcoritamab is active in large B cell lymphomas	19
Laparoscopic hemihepatectomy is safe and effective	18
Neoadjuvant chemoimmunotherapy is effective in locally advanced cervical cancer	18
Menin–KMT2A interaction inhibitor shows promise	16
Adjuvant chemotherapy improves OS in UTUC	15
Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	15
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia	14
The microbiota in radiotherapy-induced cancer immunosurveillance	14
Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma	14
Sacituzumab tirumotecan improves OS in EGFR TKI-resistant NSCLC	14
Platinum-ineligible: atezolizumab preferable	13
The age of foundation models	13
Synthetic lethal strategies for the development of cancer therapeutics	13
Pembrolizumab for HER2+ gastric cancer	13
HER2-targeted therapies beyond breast cancer — an update	13
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?	12
Early promising results with the novel KRASG12C inhibitor divarasib	12
Pembrolizumab reduces recurrence risk in stage II melanoma	12
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients	12
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?	11
Will I feel better? Raising the bar for quality of life in oncology	11

Getting the right combination to break the epigenetic code	11
Precision oncology for KRASG12C-mutant colorectal cancer	11
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics	11
The next generation of immunotherapies for lung cancers	11
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC	10
Docetaxel-based CRT improves survival in cisplatin-ineligible patients	10
Engaging results with glofitamab in DLBCL	10
PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations	10
SBRT feasible for oligometastatic RCC	10
Risk-adjusting away volume as a quality metric for surgical oncology: a perspective worth re-visiting	10
Cancer mRNA vaccines: clinical advances and future opportunities	10
T-DXd is effective after T-DM1	10
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck	9
Fertility support for patients with gynaecological cancers — a vital but neglected issue	8
Benefit from huCAR19-IL18 cells in patients with CD19+ lymphomas after CAR T cells	8
Dabrafenib–trametinib moves to the first line in low-grade glioma	8
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges	8
Perioperative immunotherapy for renal cell carcinoma: looking beyond the data	8
Thermal immuno-nanomedicine in cancer	8
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer	8
A new first-line option for advanced-stage anal squamous cell carcinoma	7
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent	7
Is NETTER-2 a practice-changing trial?	7
Cerebrospinal fluid liquid biopsies for medulloblastoma	7
Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer	7
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer	7
HER2-directed therapy improves urothelial cancer outcomes	7
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks	6
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma	6
Functional precision oncology using patient-derived assays: bridging genotype and phenotype	6
The molecular blueprint of targeted radionuclide therapy	6
A new era for glioma therapy — targeting mutant IDH	6
Molecular tumour boards — current and future considerations for precision oncology	6
Gut microbes as biomarkers of ICI response — sharpening the focus	6
New treatment strategies for advanced-stage gastrointestinal stromal tumours	6
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	5
SUNLIGHT illuminates the activity of bevacizumab	5
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins	5
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions	5
Targeting the glioblastoma resection margin with locoregional nanotechnologies	5
Targeting cuproplasia and cuproptosis in cancer	5
Synergy of EphB2 and PD-1 blockade	5
Perioperative therapy effective in high-risk HCC	5
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management	5
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3	5
Dostarlimab effective in dMMR LARC	5
Promising results with zongertinib in advanced-stage HER2-mutant NSCLC	5
Criteria for the translation of radiomics into clinically useful tests	5
Circulating tumour cells for early detection of clinically relevant cancer	5
Maintenance capecitabine is beneficial in NPC	4
The SONIA trial shows the power and challenges of academic research	4
Neoantigen vaccines at the crossroads: lessons from AMPLIFY-201	4
Leptomeningeal metastatic disease: new frontiers and future directions	4
Blinatumomab improves outcomes in infant ALL	4
Prospective insights on the use of bTMB	4
Asciminib is safe and effective in patients with newly diagnosed CML	4
Early promising results with addition of an ICI and an anti-angiogenic to TACE	4
FDA approvals in 2024: new options for patients across cancer types and therapeutic classes	4
Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL	4
Darolutamide combo is a sensible option for mHSPC	4
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer	4
Transanal TME noninferior to the laparoscopic approach	4
Combination neoadjuvant chemotherapy improves outcomes	4
Towards equitable AI in oncology	4
AI accurately identifies targetable alterations in lung cancer histological images	4
Adjuvant S-1 extends OS in biliary tract cancers	4
Adjuvant nivolumab shows promise in MCC	3
Novel combination delivers prolonged OS	3
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?	3
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours	3
Emerging importance of HER3 in tumorigenesis and cancer therapy	3
THOR provides new data on the efficacy of erdafitinib	3
The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain	3
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology	3
Clinical relevance of tumour-associated macrophages	3
Tovorafenib effective against low-grade gliomas harbouring BRAF fusions	3
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach	3
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy	3
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer	3
Vorasidenib: a new hope or a false promise for patients with low-grade glioma?	3
CAR T cells show superiority over standard therapies for RRMM	3
NIR-II light in clinical oncology: opportunities and challenges	3
Progress in systemic therapy for advanced-stage urothelial carcinoma	3
CABINET presents cabozantinib as a new treatment option for NETs	3
Radiotherapy can be omitted for older patients with low-risk disease	3
Novel assessment of epigenetic imprinting biomarkers for the diagnosis of thyroid nodules	3
Envisioning trans-inclusive and trans-specific cancer care	3
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer	3
From WCC 2022	3
Rare molecular subtypes of lung cancer	3
Bemarituzumab enters the FIGHT	3
Benefit with ESCAT-guided treatment	3
Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?	3
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome	3
Extended neoadjuvant dostarlimab provides durable benefit in resectable dMMR solid tumours	3